Optimizing Outcomes in Patients with Diabetic Kidney Disease - POCN
:Home>>Optimizing Outcomes in Patients with Diabetic Kidney Disease

Optimizing Outcomes in Patients with Diabetic Kidney Disease

Nephrology | January 15, 2021

Credits:

0.75 Pharmacology
1.0 AANP Contact Hours
1.0 AMA PRA Category 1 Credit(s)™
Start Course

Launch Date:

January 15, 2021

Expiration Date:

January 14, 2022

primary audience:

Nurse practitioners, Other clinicians involved in the care of patients with diabetic kidney disease., Physician assistants, Primary care physicians

Relevant Terms:

Diabetes; chronic kidney disease; diabetic kidney disease

course faculty

Robert Toto, MD

Robert Toto, M.D., is the Mary M. Conroy Professor of Kidney Disease in UT Southwestern’s Department of Internal Medicine. He specializes in kidney disease treatment and research. Dr. Toto also is the Associate Dean of Clinical and Translational Research in the Graduate School of Biomedical Sciences; the Director of the Center for Translational Medicine; and the Medical Director of UT Southwestern’s Multi-Specialty Clinic.

Dr. Toto earned his medical degree at the University of Illinois Medical School. He completed a residency in internal medicine at the University of Michigan and Baylor College of Medicine and then received advanced training in nephrology through fellowships at the U.S. Public Health Service Hospital and UT Southwestern Medical Center. He joined the UT Southwestern faculty in 1983.

He is nationally and internationally known for clinical research and teaching. He has been awarded numerous teaching awards from medical students and residents at UT Southwestern and is a regular speaker at national and international nephrology meetings on a variety of topics in renal disease. He has served on program committees for the American Society of Nephrology, the International Congress of Nephrology, and the National Kidney Foundation and is actively involved with training and research policy development at the national level through the American Society of Nephrology and the National Institutes of Health.

Dr. Toto’s research interests include detection, prevention, and treatment of progressive kidney diseases, including diabetes and hypertension. He has an active laboratory and has been intimately involved in the design and conduct of phase I clinical trials as well as several major outcomes trials in patients with chronic kidney disease, including NIH- and nonfederally funded trials (eg, the AASK trial, the HEMO study, and TREAT). He has authored more than 100 original articles and textbook chapters related to diagnosis and management of hypertension and kidney diseases.

Javier Morales, MD, FACP, FACE

Dr. Morales is in private practice with the Advanced Internal Medicine Group in East Hills, NY. After having graduated from UMDNJ-NJ Medical School, his medical training included residencies at Memorial Sloan-Kettering Cancer Center and North Shore University Hospital where he served as Chief Medical Resident.  In addition to numerous publications, he has served as principal investigator for several different studies and clinical trials. He is active in the educational sector and presents at continuing education symposia both nationally and internationally.  Dr. Morales serves as clinical instructor for several nurse practitioner programs, physician assistant programs, and the internal medicine residency program at Northwell Health at North Shore University Hospital and Winthrop University Hospital. He is a also Clinical Assistant Professor of Medicine at the Northwell School of Medicine at Hofstra University. 

learning objectives
1. Utilize recommended screening strategies to ensure early diagnosis of chronic kidney disease (CKD) in patients with diabetes, including the use of urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR).
2. Discuss how diabetic kidney disease (DKD) confers a high risk of cardiovascular disease (CVD), renal events, and associated mortality and implications for management.
3. Discuss the role of inflammation, fibrosis and the mineralocorticoid receptor in the progression of CKD.
4. Incorporate current treatment approaches and discuss novel treatment approaches based on current and emerging data, to optimize the care of patients with type 2 diabetes and decrease the risk of progression of DKD.
course information

Course Summary

Diabetic kidney disease (DKD), is estimated to affect 20-40% of patients with diabetes mellitus and is the leading cause of end-stage renal disease (ESRD). All-cause mortality in patients with DKD is 30-fold higher than in individuals who have diabetes without chronic kidney disease (CKD), and many of these deaths are due to cardiovascular disease (CVD), rather than to ESRD. Treatment for DKD recently evolved to include sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which have demonstrated cardiorenal benefits. Emerging treatments such as non-steroidal selective mineralocorticoid receptor antagonists (MRAs) have the potential to further reduce CVD risk and DKD progression. As newer agents begin to emerge to further reduce renal risk in patients with diabetes, clinicians need to be aware of them and their MOA so they can rapidly integrate them into practice as they become available. Using video clips taken from a live broadcast presented as part of Emerging Challenges and Clinical Updates in Primary Care 2020, this activity will address strategies to screen for DKD, discuss the impact of inflammation and fibrosis on cardiovascular risk, and identify treatment approaches to optimize care of patients with type 2 diabetes and decrease risk of progression of DKD.

 

Faculty

Javier Morales, MD, FACP, FACE

Clinical Associate Professor of Medicine

Donald and Barbara Zucker School of Medicine at Hofstra/Northwell University

Vice President

Advanced Internal Medicine Group, P.C.

East Hills, NY

 

Robert Toto, MD

Associate Dean, Translational Science

Professor Internal Medicine

UT Southwestern Medical Center

Dallas, TX

 

Planning Committee

Sandy Bihlmeyer, Med

Senior Project Manager

National Association for Continuing Education

Plantation, FL

 

Michelle Frisch, MPH, CHCP

Vice President, Operations

National Association for Continuing Education

Plantation, FL

 

Joshua F. Kilbridge

President and Creative Director

Kilbridge Associates

San Francisco, CA

 

Sheila Lucas, CWEP

Activity Director

National Association for Continuing Education

Plantation, FL

 

Laurl Ann Matey, MSN, RN, CHPN

Medical Director

National Association for Continuing Education

Plantation, FL

 

Gregg Sherman, MD

Chief Medical Officer/Course Director

National Association for Continuing Education

Plantation, FL

 

Angela Golden, DNP, FNP-C, FAANP

Family Nurse Practitioner

NP Obesity Treatment Clinic and NP from Home, LLC

Assistant Professor (Ret), Northern Arizona University

Past President, American Association of Nurse Practitioners

Munds Park, AZ

 

Accreditation Information

The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 1.0 contact hour(s) (which includes .75 hour(s) of pharmacology).

https://lh5.googleusercontent.com/W4TH8VFS_NB_ovZ6S4P0o_oWP9k_PQQ8VhCEHN49mbpyPZ8ecU4yq2NL2VbRDBoalMU24wm_RTc1dHrN2y464-rVaM2tY4fPV5aodPqCF9_pEDobuf-tLJTyndJT6wuz54Omm0BuiDWLiSebeA

 

Policy on Faculty and Provider Disclosure

Educational programs sponsored by the National Association for Continuing Education (NACE) must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a NACE-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity. Any potential conflicts of interest will be resolved prior to the activity.

 

Per the ACCME, a Commercial Interest is defined as an entity producing, marketing, re-selling or distributing health care goods or services consumed by or used on, patients. Providers of clinical service directly to patients are not considered to be commercial interests – unless the provider of the clinical service is owned, or controlled by, a defined commercial interest.

 

Resolution of Personal Conflicts of Interest

NACE requires disclosure of relevant financial relationships with the commercial interest from course directors, faculty, members of the activity planning committee, and others in a position to control the content of the educational activity. Any individual who refuses to disclose his or her relationships will be disqualified from any involvement in the planning, development, teaching/presenting, managing, or evaluation of the educational activity.

 

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

 

Javier Morales has disclosed the following financial relationships:

  • Consultant: Novo Nordisk, Lilly, Mylan, Abbott, Intarcia, AstraZeneca, Boehringer Ingelheim
  • Advisory Board: Novo Nordisk, Lilly, Intarcia, Boehringer Ingelheim, AstraZeneca, Janssen, Bayer Pharmaceuticals
  • Speaker Bureau: Novo Nordisk, Lilly, AstraZeneca, Boehringer Ingelheim, Mylan, Janssen

 

Robert Toto has disclosed the following financial relationships:

  • Consultant: Akebia Therapeutics AstraZeneca, Bayer Pharmaceuticals, Otsuka Pharmaceutical, Quest Diagnostics, Reata Pharmaceuticals, Relypsa, Inc., Medscape
  • Advisory Board Member: Reata Pharmaceuticals, Medscape
  • Speaking/Teaching:  Medscape, NACE

 

The planning committee reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Sandy Bihlmeyer has no relevant conflicts of interest with any ACCME-defined commercial interest

Michelle Frisch has no relevant conflicts of interest with any ACCME-defined commercial interest.

Joshua F. Kilbridge has no relevant conflicts of interest with any ACCME-defined commercial interest.

Sheila Lucas has no relevant conflicts of interest with any ACCME-defined commercial interest.

Laurl Ann Matey has no relevant conflicts of interest with any ACCME-defined commercial interest.

Angela Golden, DNP, FNP-C, FAANP, Activity Planning Committee, has no relevant conflicts of interest with any ACCME-defined commercial interest.

Gregg Sherman has no relevant conflicts of interest with any ACCME-defined commercial interest.

 

Statement of Commercial Support:

This educational activity is supported in part by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

 

This activity is presented by National Association for Continuing Education.

 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the posttest and program evaluation. Your posttest will automatically be graded. If you successfully complete the posttest (score of 75% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 75%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest.

 

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

 

COURSE VIEWING REQUIREMENTS

Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above

For video playback, install the latest version of Flash or Quicktime.

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

 


Go to Top